MeSH tree: D12.776.124.790.651.114.224.060.829
Early results from preclinical studies and a clinical trial led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center and Stanford Medicine suggest that combining targeted radiation therapy with an experimental ...
Mar 27, 2026
0
6
For patients with asthma, receipt of immune checkpoint inhibitor (ICI) therapy for melanoma or renal cell carcinoma is not associated with an increased risk for exacerbations, according to a study presented at the annual ...
Mar 5, 2026
0
4
Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence within the bladder, according ...
Feb 27, 2026
0
27
A new UCLA investigator-initiated study has found that adding immunotherapy to standard chemotherapy before surgery is safe and shows promise for some patients with borderline-resectable pancreatic cancer, a disease that ...
Feb 17, 2026
0
9
Patients with early-stage Hodgkin lymphoma had impressive response rates when treated with a novel combination of therapies—brentuximab vedotin and nivolumab combined with chemotherapy drugs doxorubicin and dacarbazine—according ...
Jan 25, 2026
0
12
Teens with advanced-stage Hodgkin lymphoma survive longer without their disease getting worse when they receive the immunotherapy nivolumab (Opdivo) instead of the immunotherapy brentuximab vedotin (brand name Adcetris) along ...
Jan 13, 2026
0
12
According to a new study, lower doses of approved immunotherapy for malignant melanoma can give better results against tumors, while reducing side effects. This is reported by researchers at Karolinska Institutet in the Journal ...
Dec 7, 2025
0
39
A new study led by researchers at the Johns Hopkins Kimmel Cancer Center found that patients with advanced basal cell carcinoma (BCC) may benefit from receiving immunotherapy earlier in the course of treatment.
Nov 18, 2025
0
11
Early data from a Phase 2 clinical trial show a combination of immunotherapy medications can activate a robust immune response and help overcome treatment resistance in patients with refractory melanoma.
Nov 7, 2025
0
19
For patients with resected stage IIIB-C or stage IV melanoma, recurrence-free survival is longer with nivolumab than ipilimumab, according to a study published online Oct. 18 in the New England Journal of Medicine to coincide ...
Oct 21, 2025
0
13
